1. Signaling Pathways
  2. Membrane Transporter/Ion Channel
  3. Monoamine Transporter
  4. Monoamine Transporter Inhibitor

Monoamine Transporter Inhibitor

Monoamine Transporter Inhibitors (25):

Cat. No. Product Name Effect Purity
  • HY-N0480
    Reserpine
    Inhibitor 99.83%
    Reserpine is an inhibitor of the vesicular monoamine transporter 2 (VMAT2).
  • HY-16771
    Valbenazine
    Inhibitor 98.91%
    Valbenazine (NBI-98854) is a vesicular monoamine transporter 2 (VMAT2) inhibitor with the Ki of 110-190 nM.
  • HY-B0590
    Tetrabenazine
    Inhibitor 98.23%
    Tetrabenazine (Ro 1-9569) is a reversible inhibitor of the vesicular monoamine transporter VMAT2 with the Kd value of 1.34 nM. Tetrabenazine can be used for research on diseases related to hyperactive movement disorders such as Huntington's disease.
  • HY-N0480A
    Reserpine hydrochloride
    Inhibitor 99.90%
    Reserpine hydrochloride is an inhibitor of the vesicular monoamine transporter 2 (VMAT2).
  • HY-107740
    Pseudoisocyanine iodide
    Inhibitor 99.92%
    Pseudoisocyanine (iodide) is a pan inhibitor of monoamine transporters and organic cation transporters with antidepressant-like activity.
  • HY-161433
    VMAT2-IN-3
    Inhibitor
    VMAT2-IN-3 (compound 10) is a potent vesicular monoamine transporter-2 (VMAT2) inhibitor with a Ki of 0.71 nM. VMAT2-IN-3 has the potential for neurological or psychiatric disease research.
  • HY-152171
    GZ-11608
    Inhibitor
    GZ-11608 is a potent and selective vesicular monoamine transporter-2 (VMAT2) inhibitor with high affinity (Ki = 25 nM). GZ-11608 decreases methamphetamine-induced dopamine release from isolated synaptic vesicles from brain dopaminergic neurons. GZ-11608 exhibits rapid brain penetration and without neurotoxicity. GZ-11608 can be used for the research of methamphetamine use disorder.
  • HY-B0590B
    (+)-Tetrabenazine
    Inhibitor 99.95%
    (+)-Tetrabenazine ((+)-TBZ; (3R,11bR)-TBZ; (3R,11bR)-Tetrabenazine) is a reversible inhibitor of vesicular monoamine transporter 2 (VMAT-2), inhibits transport by VMAT2 with 10-fold greater potency than transport by VMAT1.
  • HY-15793
    NBI-98782
    Inhibitor 98.56%
    NBI-98782 is a high affinity and selectivity vesicular monoamine transporter 2 (VMAT2) inhibitor with a Ki of 3 nM. NBI-98782 has antipsychotic activity.
  • HY-B1704
    Nisoxetine
    Inhibitor 98.28%
    Nisoxetine is a potent and selective inhibitor of noradrenaline transporter (NET), with a Kd of 0.76 nM. Nisoxetine is an antidepressant and local anesthetic, it can block voltage-gated sodium channels.
  • HY-B1704A
    Nisoxetine hydrochloride
    Inhibitor 99.81%
    Nisoxetine hydrochloride is a potent and selective inhibitor of noradrenaline transporter (NET), with a Kd of 0.76 nM. Nisoxetine hydrochloride is an antidepressant and local anesthetic, it can block voltage-gated sodium channels.
  • HY-110165
    hENT4-IN-1
    Inhibitor 98.14%
    hENT4-IN-1 is a potent and selective human ENT4 (equilibrative nucleoside transporter 4) inhibitor with an IC50 of 74.4 nM.
  • HY-117883
    GZ-793A
    Inhibitor 99.50%
    GZ-793A is an orally active and selective vesicular monoamine transporter-2 (VMAT2) inhibitor, with an Ki of 0.029 µM. GZ-793A inhibits the neurochemical effects of methamphetamine (METH)-induced dopamine release. GZ-793A can be used for research of METH addiction.
  • HY-B0590A
    Tetrabenazine Racemate
    Inhibitor ≥98.0%
    Tetrabenazine Racemate (Ro 1-9569 Racemate) is a selective and reversible inhibitor of vesicular monoamine transporter-2 (VMAT-2).
  • HY-B0590S
    Tetrabenazine-d6
    Inhibitor ≥99.0%
    Tetrabenazine-d6 (Deutetrabenazine) is a deuterium-labled Tetrabenazine (HY-B0590), is the first deuterium approved worldwide for the research of Huntington's disease, or other hyperkinetic movement disorders.
  • HY-B0590E
    Tetrabenazine mesylate
    Inhibitor
    Tetrabenazine (Ro 1-9569) mesylate is a reversible inhibitor of the vesicular monoamine transporter VMAT2 with the Kd value of 1.34 nM. Tetrabenazine mesylate can be used for research on diseases related to hyperactive movement disorders such as Huntington's disease.
  • HY-N0480S
    Reserpine-d9
    Inhibitor
    Reserpine-d9 is the deuterium labeled Reserpine. Reserpine is an inhibitor of the vesicular monoamine transporter 2 (VMAT2).
  • HY-148863
    Cavα2δ1&NET-IN-2
    Inhibitor
    Cavα2δ1&NET-IN-2 (Compound 45CS) is a dual inhibitor of the α2δ‑1 subunit of voltage-gated calcium channels (Cavα2δ-1) and the norepinephrine transporter (NET). Cavα2δ1&NET-IN-2 inhibits Cavα2δ-1 with a Ki of 454 nM. Cavα2δ1&NET-IN-2 inhibits NET with a Ki of 59 nM and IC50 of 7 nM. Cavα2δ1&NET-IN-2 can be used for research of pain.
  • HY-148862
    Cavα2δ1&NET-IN-1
    Inhibitor
    Cavα2δ1&NET-IN-1 (Compound 59S) is a dual inhibitor of the α2δ‑1 subunit of voltage-gated calcium channels (Cavα2δ-1) and the norepinephrine transporter (NET). Cavα2δ1&NET-IN-1 inhibits Cavα2δ-1 with a Ki of 112 nM. Cavα2δ1&NET-IN-1 inhibits NET with a Ki of 383 nM and IC50 of 67 nM. Cavα2δ1&NET-IN-1 can be used for research of pain.
  • HY-16771A
    Valbenazine tosylate
    Inhibitor
    Valbenazine tosylate (NBI-98854 tosylate) is a vesicular monoamine transporter 2 (VMAT2) inhibitor with the Ki of 110-190 nM.